IP Library Granted Patent US 10,689,670
Granted Patent B2
US 10,689,670 · App. 16/309,422 · Granted Jun 23, 2020

Recombinant yeast cell

Inventors: Ioannis Papapetridis (Delft, NL); Antonius Jeroen Adriaan Van Maris (Stockholm, SE); Jacobus Thomas Pronk (Delft, NL); Paulus Petrus De Waal (Echt, NL); Niels Lauret (Echt, NL); Maarten Dirk Verhoeven (Delft, NL); Jozef Petrus Johannes Schmitz (Echt, NL)
Assignee: DSM IP ASSETS B.V.
C12P7/06C12N1/16C12N9/1205C12N9/88C12N15/81C12R1/645C12Y207/01019C12Y401/01039Y02E50/17
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,689,670
App. No.
16/309,422
Granted
Jun 23, 2020
Kind
B2
Abstract

The present invention describes a recombinant yeast cell functionally expressing one or more heterologous nucleic acid sequences encoding for ribulose-1,5-phosphate carboxylase/oxygenase (EC4.1.1.39; Rubisco), and optionally one or more molecular chaperones for Rubisco, and one or more phosphoribulokinase (EC2.7.1.19; PRK), wherein the phosphoribulokinase is under control of a promoter (the “PRK promoter”) that enables higher expression under anaerobic conditions than under aerobic conditions.

Claims (18)

1. A recombinant yeast cell functionally expressing one or more heterologous nucleic acid sequences encoding for ribulose-1,5-phosphate carboxylase/oxygenase (EC4.1.1.39; Rubisco) and one or more phosphoribulokinase (EC2.7.1.19; PRK), wherein the phosphoribulokinase is under control of a promoter, which has a PRK expression ratio anaerobic/aerobic of 2 or more, and wherein the PRK promoter comprises, in a sequence thereof, one or more of: NNNATTGTTNNN (SEQ ID NO:120); TCGTTYAG (SEQ ID NO:121); AAAAATTGTTGA (SEQ ID NO:122); or TCGTTYAG (SEQ ID N0:121) and AAAAATTGTTGA (SEQ ID NO:122).

2. The recombinant yeast cell according to claim 1 , wherein the PRK promoter is ROX1 (“regulation by oxygen 1”)-repressed.

3. The recombinant yeast cell according to claim 1 , wherein the PRK promoter has one or more ROX1 binding motif.

4. The recombinant yeast cell according to claim 1 , wherein the PRK promoter is the native promoter of a gene selected from the group consisting of FET4 (FErrous Transport; YMR319C), ANB1 (ANaeroBically induced; YJR047C), YHK8 (YHR048W), DAN1 (Delayed ANaerobic; YJR150C), AAC3 (ADP/ATP Carrier; YBR085W), TIR2 (Tlp1-Related; YOR010C), DIP5 (DIcarboxylic amino acid Permease; YPL265W), HEM13 (HEMe biosynthesis; YDR044W), YNR014W, YAR028W, FUN 57, COX5B (Cytochrome c OXidase; YIL111W), OYE2 (Old Yellow Enzyme; YHR179W), SUR2 (SUppressor of Rvs161 and rvs167 mutations; YDR297W), FRDS1 (Fumarate ReDuctase; YEL047C), PIS1 (Phosphatidyl Inositol Synthase; YPR113W), LAC1 (Longevity-Assurance gene Cognate (LAG1 Cognate); YKL008C), YGR035C, FRT2 (Functionally Related to TCP1; YAL028W), EUG1 (ER protein Unnecessary for Growth; YDR518W), HEM14 (HEMe biosynthesis; YER014W), ISU2 (IscU homolog; YOR226C), ERG26 (ERGosterol biosynthesis; YGL001C), MLO1 (Mitochondrially LOcalized protein; YMR252C), and SML1 (Suppressor of Mec1 Lethality; YML058W).

5. The recombinant yeast cell according to claim 4 , wherein the PRK promoter is the native promoter of a gene selected from the group consisting of FET4, ANB1, YHR048W, DAN1, AAC3, TIR2, DIP5 and HEM13.

6. The recombinant yeast cell according to claim 1 , wherein the PRK promoter is the native promoter of a gene selected from the group consisting of TIR2, DAN1, TIR4 (YOR009W), TIR3 (YIL011W), PAU7 (YAR020C), PAU5 (YFL020C), YLL064C, YGR294W, DAN3 (YBR301W; PAU24), YIL176C, YGL261C, YOL161C, PAU1 (YJL223C), PAU6 (YNR076W), DAN2 (YLR037C; PAU23), YDR542W, YIR041W, YKL224C, PAU3 (YCR104W), YLL025W, YOR394W, YHL046C, YMR325W, YAL068C, YPL282C, PAU2 (YEL049W), and PAU4 (YLR461W).

7. The recombinant yeast cell according to claim 6 , wherein the PRK promoter is the native promoter of a gene selected from the group consisting of TIR2, DAN1, TIR4, TIR3, PAU7, PAU5, YLL064C, YGR294W, DAN3, YIL176C, YGL261C, YOL161C, PAU1, PAU6, DAN2, YDR542W, YIR041W, YKL224C, PAU3, and YLL025W.

8. The recombinant yeast strain according to claim 1 , wherein the PRK promoter is a synthetic oligonucleotide.

9. The recombinant yeast cell according to claim 1 , wherein the PRK promoter enables expression only during anaerobic conditions.

10. The recombinant yeast cell according to claim 1 , wherein the PRK promoter is the promoter of ANB1; DAN1; or ANB1 and DAN1.

11. The recombinant yeast cell according to claim 1 , wherein the Rubisco is under a constitutive promoter.

12. The recombinant yeast cell according to claim 1 in which:

one or more genes of a non-oxidative branch of pentose phosphate pathway are overexpressed;

the yeast cell comprises a deletion or disruption of a glycerol-3-phosphate dehydrogenase (GPD) gene; or

one or more genes of a non-oxidative branch of pentose phosphate pathway are overexpressed and the yeast cell comprises a deletion or disruption of a glycerol-3-phosphate dehydrogenase (GPD) gene.

13. A process for preparing an organic compound, comprising converting a carbon source using the recombinant yeast cell according to claim 1 , thereby forming the organic compound.

14. The recombinant yeast cell according to claim 1 , further functionally expressing one or more heterologous nucleic acid sequences encoding one or more molecular chaperones for Rubisco.

15. The process of claim 13 , wherein the organic compound is an alcohol and the carbon source is a carbohydrate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2023
From: DSM IP ASSETS B.V.
To: DANISCO US INC.
Reel/Frame 066005/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2018
From: PAPAPETRIDIS, IOANNIS; VAN MARIS, ANTONIUS JEROEN ADRIAAN; PRONK, JACOBUS THOMAS; DE WAAL, PAULUS PETRUS; LAURET, NIELS; VERHOEVEN, MAARTEN; SCHMITZ, JOZEF PETRUS JOHANNES
To: DSM IP ASSETS B.V.
Reel/Frame 047855/0411 →
Priority Claims (1)
EP 16174382 · Jun 14, 2016 · regional
Continuity (1)
Related Publication 20190249201A1 · Aug 15, 2019
Cited By (2)
US 12,215,325 US 12,398,398